Why Is Liquidia Stock Trading Higher On Tuesday?
1. LQDA reported a Q2 loss of 49 cents, missing expectations. 2. Sales reached $8.84 million, beating the consensus of $3.86 million. 3. FDA approved Yutrepia, now shipping to U.S. customers. 4. Interim data from clinical trials shows promising findings for Yutrepia. 5. LQDA stock gained 14.13%, trading at $24.20.